BIIB - Biogen Inc. Stock Price and Quote

BIIB [NASD]

Healthcare | Drug Manufacturers - General | USA

Index	S&P 500	P/E	14.78	EPS (ttm)	19.63	Insider Own	0.10%	Shs Outstand	144.40M	Perf Week	1.51%
Market Cap	42.04B	Forward P/E	18.40	EPS next Y	15.77	Insider Trans	-7.14%	Shs Float	143.01M	Perf Month	5.57%
Income	2.86B	PEG	-	EPS next Q	3.51	Inst Own	88.60%	Short Float / Ratio	1.32% / 1.52	Perf Quarter	3.44%
Sales	10.36B	P/S	4.06	EPS this Y	-58.10%	Inst Trans	0.83%	Short Interest	1.89M	Perf Half Y	35.42%
Book/sh	88.47	P/B	3.28	EPS next Y	-7.90%	ROA	11.80%	Target Price	322.30	Perf Year	32.09%
Cash/sh	33.89	P/C	8.56	EPS next 5Y	-3.70%	ROE	24.50%	52W Range	187.16 - 311.88	Perf YTD	4.75%
Dividend	-	P/FCF	18.73	EPS past 5Y	-9.30%	ROI	15.30%	52W High	-6.99%	Beta	0.22
Dividend %	-	Quick Ratio	2.10	Sales past 5Y	-0.80%	Gross Margin	77.20%	52W Low	54.99%	ATR	6.38
Employees	9610	Current Ratio	2.50	Sales Q/Q	-9.70%	Oper. Margin	23.70%	RSI (14)	55.86	Volatility	1.70% 2.38%
Optionable	Yes	Debt/Eq	0.49	EPS Q/Q	253.70%	Profit Margin	27.60%	Rel Volume	0.72	Prev Close	291.92
Shortable	Yes	LT Debt/Eq	0.49	Earnings	Feb 15 BMO	Payout	0.00%	Avg Volume	1.24M	Price	290.08
Recom	2.20	SMA20	2.76%	SMA50	0.45%	SMA200	21.85%	Volume	894,098	Change	-0.63%

Oct-26-22

Upgrade

Goldman

Neutral → Buy

$220 → $370

Oct-13-22

Upgrade

Stifel

Hold → Buy

$223 → $299

Oct-07-22

Upgrade

Argus

Hold → Buy

$300

Sep-28-22

Upgrade

Robert W. Baird

Neutral → Outperform

$224 → $340

Sep-28-22

Upgrade

Mizuho

Neutral → Buy

$207 → $270

Sep-28-22

Upgrade

BMO Capital Markets

Market Perform → Outperform

$217 → $360

Apr-18-22

Upgrade

Wells Fargo

Equal Weight → Overweight

$235 → $265

Mar-08-22

Downgrade

Stifel

Buy → Hold

$304 → $223

Mar-03-22

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$227 → $248

Feb-04-22

Reiterated

Wolfe Research

Peer Perform

$244 → $217

Show Previous Ratings

Jan-27-23 09:57AM	Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance Zacks
Jan-26-23 07:22PM	UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Reuters
06:30PM	Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimers Disease Accepted by European Medicines Agency GlobeNewswire
07:30AM	Is Biogen Stock a Buy Now? Motley Fool
05:54AM	The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug American City Business Journals
10:37AM	Loading…
Jan-25-23 10:37AM	12 Cheap Biotech Stocks To Buy Insider Monkey
05:57AM	Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback? Motley Fool
Jan-24-23 06:00PM	Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know Zacks
12:10PM	Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again Zacks
Jan-20-23 04:04PM	In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug Investor's Business Daily
11:21AM	The FDA Rejected Lillys Alzheimers Drug. Why Its Only a Setback. Barrons.com
09:23AM	Why the FDA didnt grant an approval to Lillys Alzheimers drug MarketWatch
05:34AM	Eli Lilly Stock Slips Lower As FDA Rejects Fast Track Approval For Alzheimer's Drug TheStreet.com
Jan-19-23 06:18PM	Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug Reuters
06:15PM	Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
09:20AM	Loading…
09:20AM	Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval Motley Fool
05:25AM	If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today Motley Fool
Jan-18-23 10:10AM	Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen Benzinga
Jan-16-23 12:33PM	Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan Zacks
Jan-15-23 07:30PM	EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN PR Newswire
Jan-14-23 10:03AM	A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them. The Wall Street Journal
Jan-12-23 06:00PM	Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know Zacks
Jan-11-23 09:38AM	Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe Zacks
05:30AM	1 Hot Growth Stock to Buy Now, and 1 to Avoid Motley Fool
Jan-10-23 06:30PM	EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE PR Newswire
04:48PM	FDA Commissioner Denies Wrongdoing in Approval Process for Biogen Alzheimers Drug Aduhelm The Wall Street Journal
05:55AM	Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval? Motley Fool
05:36AM	Biogen CEO Viehbacher outlines a path, including immunology, rare diseases American City Business Journals
05:15AM	What's next for Leqembi, the new Biogen-Eisai Alzheimer's drug? American City Business Journals
Jan-09-23 07:20PM	Shares of Japan's Eisai surge after FDA approves Alzheimer's drug Reuters
06:15PM	Loading…
06:15PM	Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
04:27PM	These Stocks Are Moving the Most Monday: Tesla, Zillow, Regeneron, Macys, and More Barrons.com
10:04AM	Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's Zacks
08:19AM	Eisai, Biogen's Alzheimer's drug price should not dent demand - analysts Reuters
05:00AM	'The threshold of a new age': CEO of local Alzheimer's group on Biogen's new drug American City Business Journals
Jan-08-23 09:00AM	With 88% ownership, Biogen Inc. (NASDAQ:BIIB) boasts of strong institutional backing Simply Wall St.
Jan-07-23 09:00AM	New Alzheimers Drug Leqembi Will Be Out of Reach for Most Patients The Wall Street Journal
03:51AM	Alzheimers Drug From Eisai, Biogen Gets FDA Accelerated Approval Bloomberg
Jan-06-23 11:30PM	Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease PR Newswire
06:56PM	FDA approves Biogen, Eisai Alzheimers drug Fox Business
05:16PM	Analyst Report: Biogen Inc. Morningstar Research
04:43PM	US STOCKS-Wall St rallies as jobs, services data calm rate hike worries Reuters
04:07PM	Biogen Gains FDA Approval For New Alzheimer's Drug, But Medicare Remains A Wild Card Investor's Business Daily
04:04PM	FDA approves Biogen-Eisai Alzheimers drug, China in talks to make Pfizer Paxlovid generic Yahoo Finance Video
03:40PM	Alzheimers Disease Treatments: What to Know About New and Future Drugs The Wall Street Journal
03:30PM	Biogen Stock Surges After Alzheimer's Approval The Wall Street Journal
03:02PM	New Alzheimers Drug Approved by FDA, Promises to Slow Disease The Wall Street Journal
02:44PM	Genetics, Alzheimer's And AI Why 2023 Could Be The Year For Biotech Stocks Investor's Business Daily
02:41PM	FDA approves treatment for people with mild forms of Alzheimers MarketWatch
02:37PM	FDA Approves Eisai and Biogens New Alzheimers Therapy Barrons.com
02:30PM	FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease PR Newswire
02:27PM	FDA approves second Biogen Alzheimer's drug American City Business Journals
02:18PM	U.S. FDA approves Eisai, Biogen Alzheimer's drug Reuters
02:18PM	Biogen Stock Halted Pending FDA Decision On Alzheimer's Treatment Investor's Business Daily
02:13PM	UPDATE 2-U.S. FDA approves Eisai, Biogen Alzheimer's drug Reuters
10:41AM	Biogen Could Get A Second Alzheimer's OK But Will Wild Card Medicare Bite? Investor's Business Daily
09:53AM	1 Stock Defying the Downturn to Buy, and 1 to Avoid Motley Fool
08:00AM	CRISPR, Genetics And AI Why 2023 Could Be The Year For Biotech Stocks Investor's Business Daily
Jan-05-23 04:15PM	Plus Therapeutics: Targeting Brain Cancer with Rifle-Shot Precision IPO-Edge.com
02:14PM	Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device Zacks
08:03AM	Biogen separates research and development into two functions MarketWatch
08:02AM	UPDATE 1-Biogen splits R&D division ahead of key decision on Alzheimer's drug Reuters
07:30AM	Biogen Names Priya Singhal as Executive Vice President, Head of Development GlobeNewswire
Jan-04-23 08:00AM	Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 26% Undervaluation? Simply Wall St.
07:30AM	Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies GlobeNewswire
Jan-03-23 07:18PM	Analyst Report: Biogen Inc. Morningstar Research
06:00PM	Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
05:02PM	IBD Stock Of The Day: How These Issues In 2023 Could Spark, Or Slam, Eli Lilly Stock Investor's Business Daily
02:47PM	Amid criticism for its handling of another Alzheimers drug, FDA will decide this week whether to approve lecanemab MarketWatch
12:37PM	The FDAs Next Call on an Alzheimers Drug Is Due This Week Barrons.com
Dec-31-22 05:52PM	Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks Insider Monkey
Dec-29-22 07:18PM	Congress Targets FDA, Biogen on Alzheimer's Drug Approval TheStreet.com
06:38PM	Committee Report Targets FDA, Biogen on Alzheimer's Treatment TheStreet.com
06:20PM	Congressional investigation reveals 'atypical,' 'inappropriate' collaboration between FDA, Biogen American City Business Journals
03:33PM	Congress faults US regulators approval of Biogen Alzheimers drug Financial Times
01:05PM	Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer's drug Reuters
01:04PM	FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimers Drug The Wall Street Journal
05:30AM	The Petri Dish: Group eyes Biogen Alzheimer's drug price, FDA rejects psych drug application American City Business Journals
Dec-28-22 06:00PM	Biogen Inc. (BIIB) Stock Moves -0.27%: What You Should Know Zacks
05:56PM	Genentech wins approval of 1st 'chemo-light' bispecific blood cancer drug American City Business Journals
12:05PM	The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock Investor's Business Daily
07:45AM	Is Biogen's Stock Too Risky to Invest in? Motley Fool
Dec-23-22 12:53PM	Roche's Follicular Lymphoma Therapy Scores FDA Approval Benzinga
11:00AM	UPDATE 1-Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report Reuters
10:05AM	Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma Zacks
09:53AM	3 Nasdaq Stocks That Are Up 25% in 3 Months Motley Fool
06:33AM	Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report Reuters
06:30AM	1 Green Flag and 1 Red Flag for Biogen Motley Fool
04:59AM	New Alzheimers Drug Could Be Priced Up to $20,000 a Year: Group Barrons.com
Dec-22-22 07:00PM	A Deadly Legacy Raises the Stakes in the War Over Fast Drug Approvals Bloomberg
06:30PM	EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA PR Newswire
01:59PM	Biogen's Alzheimer's Antibody Might Have A Third Death Associated With Benzinga
Dec-21-22 05:50PM	Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know Zacks
Dec-19-22 07:30AM	Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration GlobeNewswire
Dec-18-22 09:04AM	The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond InvestorPlace
06:45AM	Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move Motley Fool
06:00AM	Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock Motley Fool
Dec-15-22 05:50PM	Biogen Inc. (BIIB) Stock Moves -1.94%: What You Should Know Zacks
Dec-14-22 11:39AM	Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines Zacks
Dec-13-22 10:39AM	15 Best S&P 500 Stocks That Dont Pay Dividends Insider Monkey

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kramer Robin	Chief Accounting Officer	Dec 08	Option Exercise	0.00	350	0	2,368	Dec 12 06:04 PM
Izzar Rachid	Head of Alzheimer's Disease	Dec 02	Option Exercise	0.00	1,710	0	3,395	Dec 06 06:37 PM
Murphy Nicole	Head of Pharm Ops and Tech	Dec 02	Option Exercise	0.00	131	0	2,807	Dec 06 06:33 PM
Gregory Ginger	EVP, Human Resources	Nov 14	Sale	300.11	5,610	1,683,617	5,711	Dec 12 08:00 PM
ALEXANDER SUSAN H	EVP Chief Legal Off & Corp Sec	Oct 27	Sale	280.70	5,532	1,552,832	39,396	Oct 28 07:19 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Sep 01	Option Exercise	0.00	4,746	0	7,801	Sep 06 07:31 PM
BIOGEN INC.	10% Owner	Aug 30	Sale	5.27	100,000	526,520	23,652,466	Aug 31 07:03 PM
BIOGEN INC.	10% Owner	Aug 29	Sale	5.33	400,000	2,130,720	23,752,466	Aug 31 07:03 PM
Murphy Nicole	Head of Pharm Ops and Tech	Aug 01	Option Exercise	0.00	1,080	0	2,919	Aug 03 05:40 PM
Kramer Robin	Chief Accounting Officer	Jul 01	Option Exercise	0.00	252	0	2,092	Jul 06 07:33 PM
Izzar Rachid	Head of Alzheimer's Disease	Jul 01	Option Exercise	0.00	504	0	2,258	Jul 06 07:28 PM
Vounatsos Michel	Chief Executive Officer	Feb 18	Option Exercise	0.00	6,191	0	70,007	Feb 23 04:21 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 18	Option Exercise	0.00	1,981	0	5,404	Feb 23 04:19 PM
Izzar Rachid	Head of Alzheimer's Disease	Feb 18	Option Exercise	0.00	594	0	1,929	Feb 23 04:16 PM
Kramer Robin	Chief Accounting Officer	Feb 18	Option Exercise	0.00	396	0	1,854	Feb 23 04:18 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 18	Option Exercise	0.00	371	0	1,768	Feb 23 04:20 PM
Guindo Chirfi	Head of Glob Prod Strat & Com	Feb 18	Option Exercise	0.00	1,981	0	8,243	Feb 23 04:15 PM
Gregory Ginger	EVP, Human Resources	Feb 18	Option Exercise	0.00	1,387	0	11,835	Feb 23 04:15 PM
ALEXANDER SUSAN H	EVP Chief Legal Off & Corp Sec	Feb 18	Option Exercise	0.00	1,485	0	45,587	Feb 23 04:14 PM
ALEXANDER SUSAN H	EVP Chief Legal Off & Corp Sec	Feb 12	Option Exercise	0.00	2,280	0	45,646	Feb 15 04:17 PM
Guindo Chirfi	Head of Glob Prod Strat & Com	Feb 12	Option Exercise	0.00	2,597	0	8,044	Feb 15 04:15 PM
Gregory Ginger	EVP, Human Resources	Feb 12	Option Exercise	0.00	1,672	0	11,422	Feb 15 04:16 PM
Kramer Robin	Chief Accounting Officer	Feb 12	Option Exercise	0.00	275	0	1,594	Feb 15 04:13 PM
Izzar Rachid	Head of Alzheimer's Disease	Feb 12	Option Exercise	0.00	351	0	1,457	Feb 15 04:14 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 12	Option Exercise	0.00	263	0	1,489	Feb 15 04:11 PM
Vounatsos Michel	Chief Executive Officer	Feb 12	Option Exercise	0.00	8,716	0	70,465	Feb 15 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience